In vitro activity of lomefloxacin as compared with ciprofloxacin. NLM AIDSLINE Important note: Information in this article was accurate in 1990. The state of the art may have changed since the publication date.

Click here to return to AIDSLINE main menu
DonateNow
Print this Article


In vitro activity of lomefloxacin as compared with ciprofloxacin.

Diagn Microbiol Infect Dis. 1989 May-Jun;12(3 Suppl):17S-20S. Unique Identifier : AIDSLINE MED/90004197
Inderlied CB; Lancero MG; Bermudez LM; Young LS; Department of Pathology, University of Southern California, Los; Angeles 90027.

Abstract: Lomefloxacin (SC47111, Searle) is a difluorinated quinolone with a comparatively long half-life and high serum concentration. This agent has good in vitro activity against Enterobacteriaceae (MIC90 = less than 2 micrograms/ml) and staphylococci (MIC90 = less than 2 micrograms/ml); the activity against Pseudomonas spp. and Pseudomonas aeruginosa is moderate to poor. On a weight basis, lomefloxacin is less active than ciprofloxacin; however, based on the ratio of the serum concentration to MIC, the activity of lomefloxacin is nearly equivalent to ciprofloxacin against many bacteria, with the exception that ciprofloxacin has good activity against most pseudomonads. Also, lomefloxacin was active against a variety of bacteria that were resistant to aminoglycosides and/or third-generation cephalosporins. A majority of strains of the Mycobacterium avium complex, isolated from AIDS patients with disseminated disease, were found to be resistant to lomefloxacin (MIC90 = greater than 8 micrograms/ml).
Keywords: Acquired Immunodeficiency Syndrome/BLOOD Anti-Infective Agents, Quinolone/*PHARMACOLOGY Ciprofloxacin/*PHARMACOLOGY Comparative Study Drug Resistance, Microbial Human Microbial Sensitivity Tests Mycobacterium avium Complex/DRUG EFFECTS/ISOLATION & PURIF Support, Non-U.S. Gov't Support, U.S. Gov't, P.H.S. JOURNAL ARTICLEKWDacquiredimmunodeficiencysyndrome/bloodanti-infectiveagents,quinolone/KWDpharmacologyciprofloxacin/KWDpharmacologycomparativestudydrugresistance,microbialhumanmicrobialsensitivitytestsmycobacteriumaviumcomplex/drugeffects/isolation&purifsupport,non-uKWDsKWDgov'tsupport,uKWDsKWDgov't,pKWDhKWDsKWDjournalarticle
900130
M9010479

Copyright © 1990 - National Library of Medicine. Reproduced under license with the National Library of Medicine, Bethesda, MD.

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, Gill Foundation, the National Library of Medicine, Quest Diagnostics, Roche and Trimeris, and donations from users like you. Always watch for outdated information. This article first appeared in 1990. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 1990. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .